Neurocrine Biosciences Reports Third Quarter 2017 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Neurocrine Bio. (NBIX) PT Raised to $90 at Cowen as Ingrezza Blows Past Expectations
November 2, 2017 6:26 AM EDTCowen analyst Phil Nadeau raised his price target on Neurocrine Bio. (NASDAQ: NBIX) to $90.00 (from $65.00) while maintaining an Outperform rating following Q3 Ingrezza sales of $45.8MM, over 4x consensus of $10.8MME, and largely reflected end-user demand.
"While Q4 will be impacted by... More
